Here are seven key notes on the company’s financial report:
1. DJO Global reported 12.7 percent net sales growth to $278.9 million in the first quarter over the same period last year. The foreign currency exchange rate negatively impacted the net sales.
2. The company’s international segment net sales reached $75.1 million in the first quarter, with France, Canada and the United Kingdom as big contributors.
3. The surgical implant segment reported $43.1 million in first quarter net sales, a 59.9 percent increase over the same period last year. Hip, knee, shoulder and cement segments had a strong quarterly performance.
4. DJO Global reported a successful uptake in the market for its new Empwr 3D Knee during the first quarter and launched the Altivate Shoulder.
5. Net loss for the quarter attributable to DJOFL was $38.3 million, up from $35.5 million over the same period last year.
6. The company reported $37.2 million in cash balances and $118.5 million in availability liquidity under its $150 million revolving credit facility as of Dec. 31, 2015.
7. DJO Global confirmed previous guidance for the 2016 revenue growing at 6 percent to 8 percent. Adjusted EBITDA growth rates are expected at 8 percent to 10 percent.
More articles on orthopedic devices:
DePuy Orthopaedics acquires BioMedical Enterprises: 5 things to know
Global sports medicine device market to reach $8.28B—8 takeaways
CJR may hit device companies hard: 7 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
